These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26535075)

  • 41. Antibacterial targets in fatty acid biosynthesis.
    Wright HT; Reynolds KA
    Curr Opin Microbiol; 2007 Oct; 10(5):447-53. PubMed ID: 17707686
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 2-Guanidino-quinazolines as a novel class of translation inhibitors.
    Komarova Andreyanova ES; Osterman IA; Pletnev PI; Ivanenkov YA; Majouga AG; Bogdanov AA; Sergiev PV
    Biochimie; 2017 Feb; 133():45-55. PubMed ID: 28011211
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Screening of Potential Lead Molecule as Novel MurE Inhibitor: Virtual Screening, Molecular Dynamics and In Vitro Studies.
    Zaveri K; Kiranmayi P
    Curr Comput Aided Drug Des; 2017; 13(1):8-21. PubMed ID: 27748170
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lipid II as a target for antibiotics.
    Breukink E; de Kruijff B
    Nat Rev Drug Discov; 2006 Apr; 5(4):321-32. PubMed ID: 16531990
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Para-(benzoyl)-phenylalanine as a potential inhibitor against LpxC of Leptospira spp.: homology modeling, docking, and molecular dynamics study.
    Pradhan D; Priyadarshini V; Munikumar M; Swargam S; Umamaheswari A; Bitla A
    J Biomol Struct Dyn; 2014; 32(2):171-85. PubMed ID: 23383626
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of a High-Throughput Screening Assay to Identify Inhibitors of the Lipid Kinase PIP5K1C.
    Wright BD; Simpson C; Stashko M; Kireev D; Hull-Ryde EA; Zylka MJ; Janzen WP
    J Biomol Screen; 2015 Jun; 20(5):655-62. PubMed ID: 25534829
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peptide ligands in antibacterial drug discovery: use as inhibitors in target validation and target-based screening.
    Lapan KA; Chapple JP; Galcheva-Gargova Z; Yang M; Tao J
    Expert Opin Ther Targets; 2002 Aug; 6(4):507-16. PubMed ID: 12223065
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multidrug-Resistant Enterococcal Infections: New Compounds, Novel Antimicrobial Therapies?
    van Harten RM; Willems RJL; Martin NI; Hendrickx APA
    Trends Microbiol; 2017 Jun; 25(6):467-479. PubMed ID: 28209400
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of Inhibitors for the Ether Lipid-Generating Enzyme AGPS as Anti-Cancer Agents.
    Piano V; Benjamin DI; Valente S; Nenci S; Marrocco B; Mai A; Aliverti A; Nomura DK; Mattevi A
    ACS Chem Biol; 2015 Nov; 10(11):2589-97. PubMed ID: 26322624
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Small molecule inhibitors of peptidoglycan synthesis targeting the lipid II precursor.
    Derouaux A; Turk S; Olrichs NK; Gobec S; Breukink E; Amoroso A; Offant J; Bostock J; Mariner K; Chopra I; Vernet T; Zervosen A; Joris B; Frère JM; Nguyen-Distèche M; Terrak M
    Biochem Pharmacol; 2011 May; 81(9):1098-105. PubMed ID: 21356201
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structure-Activity Relationships of the MEPicides: N-Acyl and O-Linked Analogs of FR900098 as Inhibitors of Dxr from Mycobacterium tuberculosis and Yersinia pestis.
    San Jose G; Jackson ER; Haymond A; Johny C; Edwards RL; Wang X; Brothers RC; Edelstein EK; Odom AR; Boshoff HI; Couch RD; Dowd CS
    ACS Infect Dis; 2016 Dec; 2(12):923-935. PubMed ID: 27676224
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibacterial and antioxidant activities for natural and synthetic dual-active compounds.
    Martelli G; Giacomini D
    Eur J Med Chem; 2018 Oct; 158():91-105. PubMed ID: 30205261
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bacterial DNA replication enzymes as targets for antibacterial drug discovery.
    Sanyal G; Doig P
    Expert Opin Drug Discov; 2012 Apr; 7(4):327-39. PubMed ID: 22458504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting the Type II Secretion System: Development, Optimization, and Validation of a High-Throughput Screen for the Identification of Small Molecule Inhibitors.
    Waack U; Johnson TL; Chedid K; Xi C; Simmons LA; Mobley HLT; Sandkvist M
    Front Cell Infect Microbiol; 2017; 7():380. PubMed ID: 28894700
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of lysine biosynthesis: an evolving antibiotic strategy.
    Hutton CA; Perugini MA; Gerrard JA
    Mol Biosyst; 2007 Jul; 3(7):458-65. PubMed ID: 17579770
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel FabH inhibitors: a patent and article literature review (2000--2012).
    Luo Y; Yang YS; Fu J; Zhu HL
    Expert Opin Ther Pat; 2012 Nov; 22(11):1325-36. PubMed ID: 22998551
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DNA gyrase inhibitors: Progress and synthesis of potent compounds as antibacterial agents.
    Khan T; Sankhe K; Suvarna V; Sherje A; Patel K; Dravyakar B
    Biomed Pharmacother; 2018 Jul; 103():923-938. PubMed ID: 29710509
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis.
    Gür ZT; Çalışkan B; Banoglu E
    Eur J Med Chem; 2018 Jun; 153():34-48. PubMed ID: 28784429
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alternative and/or integrative therapies for pneumonia under development.
    Cazzola M; Page CP; Matera MG
    Curr Opin Pulm Med; 2004 May; 10(3):204-10. PubMed ID: 15071372
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.